CBDV is an abbreviation for Cannabidivarin. It is a cannabinoid with zero psychoactive effects, just like CBD. CBDV has very high therapeutic effects, but it doesn’t get the user high. However, there is not much research on the therapeutic benefits of non-psychoactive cannabis mainly due to the illegality of marijuana.
The CBDV-rich cannabis is found mainly in Pakistan. It is very similar to CBD. Mexican cannabis has also been found to contain CBDV. Looking at the scientific structure, CBDV is seen to have 30 stereoisomers and 7 double bond isomers, just like CBD. It doesn’t have any psychedelic properties, therefore it is perfect for people who respond negatively to large doses of tetrahydrocannabinol (THC).
CBDV comes before THCV. Studies have shown that CBDV converts to THCV once it interacts with acids. This is of great interest to scientists as research is ongoing on the anti-diabetic properties of THCV.
Not many studies have been carried out on the effect of THCV on the body, but researchers are currently studying its effects on various conditions including epilepsy, schizophrenia, and cancer.
Most breeders do not have strains that are rich in CBDV. However, if a particular strain of cannabis is rich in CBD, then it will have some significant amount of CBDV. Although the majority of cannabis strains are rich in THC, it is interesting to note that the number of cannabis plants with CBDV is gradually increasing globally.
While we do not know the exact health benefits of CBDV, studies have shown that this cannabinoid may have very positive effects on human health.
The Healing Effects of CBDV
Not many studies have been performed on the therapeutic effects of CBDV. However, it is worth noting that research is ongoing on the subject. CBDV plays vital roles in treating nausea and seizures from illnesses such as epilepsy. Studies have shown that CBDV can successfully alleviate nausea.
A study published by the National Institute on Cannabidivarin has shown that CBDV considerably reduces the impact of seizures induced by epilepsy. Findings from this study showed that CBDV has anticonvulsant and non-psychedelic effects on seizures induced chemically, hence making it an interesting subject for further research.
The Most Potent Therapeutic Effects of CBDV Are Seen in Nausea, Epilepsy, and Bones
Studies have found that the above-mentioned are the three most common conditions where the therapeutic effects of CBDV are clearly expressed. It is quite unfortunate that CBDV is somewhat rare, but recent studies have motivated breeders to start the cultivation of cannabis with CBDV.
Nausea: The effects of CBDV was tested on nausea using lithium chloride on animal models. The response given by the rodents to this treatment was gawking, which is their way of expressing the desire to vomit as they do not have the ability to vomit like humans. The experiment showed that CBDV does have the ability to slow down gawking in rodents. This was an indication that the compound has similar anti-nausea properties as other cannabis-based compounds.
Bones: CBDV can boost the growth and development of bones. It has components that stimulate bone growth. This would be exciting news for those with fractures. According to research, the compound has the potential to toughen the cartilage bridge that links the fragments of structures. Because it has the ability to stimulate stem cells, it implies that CBDV could help to produce or restore bones.
Epilepsy: Research has shown that at least 50 million people suffer from epilepsy globally. Clinical studies have shown that CBD has the ability to decrease seizures. Research has also shown that CBDV has anticonvulsive potentials. A study conducted in 2012 was published highlighting the anticonvulsive effects of CBDV on seizures in rodents. This was done by the National Institutes of Health. A 2014 study showed that CBDV slows down electrical waves in response to seizure activities in brain slices outside of the body. This is a very important research and shows that CBDV may play a critical role in the treatment of epilepsy.
Alexander SPH, Mathie A, Peters JA. Guide to receptors and channels (GRAC) Br J Pharmacol. 2011; 164:S1–S324.
BNF. British National Formulary. 62nd edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2011.
Cheng YC, Prusoff WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22:3099–3108
Chesher G, Jackson D. Anticonvulsant effects of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacology (Berl) 1974; 37:255–264.